Janus Henderson Group PLC Ligand Pharmaceuticals Inc Transaction History

Janus Henderson Group PLC

$182 Billion
Q2 2024

A detailed history of Janus Henderson Group PLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 1,008,733 shares of LGND stock, worth $106 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

1,008,733

Previous 1,008,477 0.03%

Holding current value

$106 Million

Previous $73.7 Million 15.3%

% of portfolio

0.05%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$68.53 - $87.91 $17,543 - $22,504	256 Added 0.03%	1,008,733 $85 Million
Q1 2024 May 15, 2024	SELL	$68.64 - $89.2 $23 Million - $29.9 Million	-334,677 Reduced 24.92%	1,008,477 $73.7 Million
Q4 2023 Feb 14, 2024	BUY	$49.57 - $72.63 $63,499 - $93,039	1,281 Added 0.1%	1,343,154 $95.9 Million
Q3 2023 Nov 14, 2023	SELL	$58.86 - $72.67 $157,862 - $194,900	-2,682 Reduced 0.2%	1,341,873 $80.4 Million
Q2 2023 Aug 14, 2023	BUY	$69.53 - $79.33 $5.89 Million - $6.72 Million	84,670 Added 6.72%	1,344,555 $96.9 Million
Q1 2023 May 15, 2023	BUY	$65.67 - $77.08 $302,870 - $355,492	4,612 Added 0.37%	1,259,885 $92.7 Million
Q4 2022 Feb 14, 2023	SELL	$61.72 - $96.74 $435,743 - $682,984	-7,060 Reduced 0.56%	1,255,273 $83.9 Million
Q3 2022 Nov 14, 2022	SELL	$0.01 - $107.56 $1,271 - $13.7 Million	-127,155 Reduced 9.15%	1,262,333 $109 Million
Q2 2022 Aug 15, 2022	BUY	$74.52 - $117.06 $31,372 - $49,282	421 Added 0.03%	1,389,488 $124 Million
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $4.94 Million - $7.88 Million	-52,018 Reduced 3.61%	1,389,067 $156 Million
Q4 2021 Feb 14, 2022	SELL	$127.69 - $165.85 $2.79 Million - $3.62 Million	-21,815 Reduced 1.49%	1,441,085 $223 Million
Q3 2021 Nov 16, 2021	BUY	$102.33 - $144.73 $1.91 Million - $2.7 Million	18,679 Added 1.29%	1,462,900 $204 Million
Q2 2021 Aug 16, 2021	BUY	$113.03 - $155.64 $21.1 Million - $29 Million	186,424 Added 14.82%	1,444,221 $189 Million
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $35.3 Million - $76.5 Million	-354,572 Reduced 21.99%	1,257,797 $192 Million
Q4 2020 Feb 16, 2021	BUY	$80.55 - $106.05 $509,720 - $671,084	6,328 Added 0.39%	1,612,369 $160 Million
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $95,560 - $135,210	1,067 Added 0.07%	1,606,041 $153 Million
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $914,405 - $1.66 Million	13,392 Added 0.84%	1,604,974 $180 Million
Q1 2020 May 14, 2020	SELL	$63.37 - $107.88 $14.3 Million - $24.4 Million	-225,892 Reduced 12.43%	1,591,582 $116 Million
Q4 2019 Feb 18, 2020	BUY	$96.94 - $113.59 $24.4 Million - $28.6 Million	251,452 Added 16.06%	1,817,474 $190 Million
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $2.01 Million - $2.81 Million	23,352 Added 1.51%	1,566,022 $156 Million
Q2 2019 Jul 31, 2019	BUY	$107.38 - $129.34 $16.9 Million - $20.4 Million	157,604 Added 11.38%	1,542,670 $176 Million
Q1 2019 Apr 30, 2019	BUY	$105.93 - $142.47 $42 Million - $56.4 Million	396,166 Added 40.06%	1,385,066 $174 Million
Q4 2018 Feb 06, 2019	BUY	$128.36 - $272.13 $11.4 Million - $24.2 Million	88,813 Added 9.87%	988,900 $134 Million
Q3 2018 Nov 09, 2018	SELL	$211.18 - $274.49 $5.7 Million - $7.42 Million	-27,014 Reduced 2.91%	900,087 $247 Million
Q2 2018 Aug 10, 2018	BUY	$150.77 - $207.98 $8.29 Million - $11.4 Million	54,990 Added 6.31%	927,101 $192 Million
Q1 2018 May 14, 2018	SELL	$138.63 - $182.62 $5.86 Million - $7.72 Million	-42,274 Reduced 4.62%	872,111 $144 Million
Q4 2017 Feb 09, 2018	BUY	$128.36 - $147.04 $20.5 Million - $23.5 Million	159,693 Added 21.16%	914,385 $125 Million
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $19.2 Million - $22 Million	159,201 Added 26.73%	754,692 $0
Q2 2017 Aug 17, 2017	BUY	N/A	595,491	595,491 $72.3 Million

Others Institutions Holding LGND

# of Institutions

247

Shares Held

17.5M

Call Options Held

61K

Put Options Held

7.8K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.77B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Ligand Pharmaceuticals Inc Transaction History